LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

GlycoMimetics Inc

Avatud

SektorTervishoid

0.25 4.17

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.23

Max

0.25

Põhinäitajad

By Trading Economics

Sissetulek

2.6M

-7.2M

Aktsiakasum

-0.112

Töötajad

4

EBITDA

399K

-5.3M

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

17M

Eelmine avamishind

-3.92

Eelmine sulgemishind

0.25

Uudiste sentiment

By Acuity

29%

71%

73 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

GlycoMimetics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. juuli 2024, 15:11 UTC

Suurimad hinnamuutused turgudel

GlycoMimetics Shares Drop 27% After Restructuring Plan, Job Cuts

Võrdlus sarnastega

Hinnamuutus

GlycoMimetics Inc Prognoos

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.2416 / 0.261Toetus ja vastupanu

Lühikene perspektiiv

Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

73 / 382 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest GlycoMimetics Inc

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.